Expert consensus statement on therapeutic drug monitoring and individualization of linezolid

Datos Bibliográficos

ID22068112
AutoresBin Lin (0000-0002-4099-309X, Second Affiliated Hospital of Zhejiang University), Yangmin Hu (Second Affiliated Hospital of Zhejiang University), Ping Xu (0000-0001-6099-1748, Ningbo First Hospital), Tao Xu (0000-0002-0501-6445, Ningbo First Hospital), Chunyan Chen (0000-0001-9220-4569, Ningbo First Hospital), Le He (0000-0002-4520-0482, Shanghai Jiao Tong University), Mi Zhou (0000-0002-9067-1101, Soochow University), Zhangzhang Chen (Sun Yat-sen University), Chunhong Zhang (0000-0002-6945-046X, Wenzhou Medical University), Xuben Yu (0000-0003-1897-4519, Wenzhou Medical University), Luo Fang (0000-0003-1187-4195, Zhejiang Cancer Hospital), Junfeng Zhu (0000-0002-6697-2035, Zhejiang Cancer Hospital), Yanlan Ji (0009-0003-2323-7019), Qun Lin (0000-0003-0209-6424), Hengbin Cao (Huzhou Central Hospital), Youqin Dai (University of Chinese Academy of Sciences), Xiaoyan Lu (0000-0001-5710-4968, University of Chinese Academy of Sciences), Changcheng Shi (0000-0002-8879-4794, Hangzhou First People's Hospital), Li Li (0000-0001-9700-9682, Zhejiang Hospital), Changjiang Wang (0000-0002-0425-7976, Jiaxing University), Xumei Li (0000-0002-0706-6542, Jiaxing University), Qiongyan Fang (Zhoushan Hospital), Jing Miao (0000-0002-5441-6314, Children's Hospital of Zhejiang University), Zhengyi Zhu (0000-0003-1166-426X, Children's Hospital of Zhejiang University), Guangyong Lin (Wenzhou Medical University), Haichao Zhan (Zhejiang University), Shiwen Lv, Shi‐Wen Lv (0000-0002-1767-5448, Zhejiang University), Yalan Zhu (Zhejiang University), Xinjun Cai (0000-0003-3606-8819, Second Affiliated Hospital of Zhejiang University), Ying Yin (0000-0001-8581-9696, Tongde Hospital of Zhejiang Province), Yin Ying, Meng Chen (0000-0003-4503-5226, Jiaxing University), Qiong Xu (0000-0002-0103-8081, Central Hospital of Putuo District), Yiwen Zhang (0009-0009-1912-0583, Zhejiang Provincial People's Hospital), Yubin Xu (0000-0003-0340-4425, Taizhou Central Hospital), Federico Pea (0000-0002-6966-7167, Azienda USL di Bologna), Saiping Jiang (0000-0001-7720-2725, First Affiliated Hospital Zhejiang University, autor de correspondencia), Haibin Dai (0000-0002-5768-2714, Second Affiliated Hospital of Zhejiang University, autor de correspondencia)
Año2022
Volumen10
Páginas967311-967311
Fecha de publicación2022-08-10
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaFrontiers in Public Health (JOURNAL)
Identificadores de la revistaISSN: 2296-2565 • E-ISSN: 2296-2565
EditorialFrontiers Media SA (PUBLISHER • CH)
DOI10.3389/fpubh.2022.967311
PMID36033811
OpenAlexW4293152033
IdiomaEN
Citas recibidas2
Referencias citadas112

Linezolid is an oxazolidinone antibacterial drug, and its therapeutic drug monitoring and individualized treatment have been challenged since its approval. With the in-depth clinical research of linezolid, we have changed our attitude toward its therapeutic drug monitoring and our view of individualized treatment. On the basis of summarizing the existing clinical studies, and based on the practical experience of each expert in their respective professional fields, we have formed this expert consensus. Our team of specialists is a multidisciplinary team that includes pharmacotherapists, clinical pharmacology specialists, critical care medicine specialists, respiratory specialists, infectious disease specialists, emergency medicine specialists and more. We are committed to the safe and effective use of linezolid in patients in need, and the promotion of its therapeutic drug monitoring

Clinical trial · Compassionate Use · Drug · Intensive care medicine · Linezolid · Therapeutic drug monitoring · Antibiotics Pharmacokinetics and Efficacy · Antimicrobial Resistance in Staphylococcus · Bacterial Identification and Susceptibility Testing · Medicine · Internal Medicine · Pharmacology